|
- Liquidia Corporation | Corporate Website
At Liquidia, we are dedicated to developing best-in-class therapies for rare cardiopulmonary diseases like pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) to help patients breathe easier and live longer
- Press releases | Liquidia Corporation
U S FDA Approves Liquidia’s YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
- About us | Liquidia Corporation
Get in touch Reach out to learn more about our products, pipeline, and careers
- Investors | Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease The company’s current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology
- Events presentations | Liquidia Corporation
Liquidia First Quarter 2024 Financial Results and Corporate Update Call May 14, 2024 8:30 AM EDT Click here for webcast 23rd Annual Needham Virtual Healthcare Conference Apr 9, 2024 1:30 PM EDT Liquidia Full Year 2023 Financial Results and Corporate Update Call Mar 13, 2024 8:30 AM EDT
- U. S. FDA Approves Liquidia’s YUTREPIA™ (treprostinil) Inhalation Powder . . .
Liquidia has completed the INSPIRE trial (NCT03399604), or Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil, an open-label, multi-center phase 3 clinical study of YUTREPIA in patients diagnosed with PAH who are naïve to inhaled treprostinil or who are transitioning from Tyvaso ® (nebulized treprostinil)
- Liquidia Corporation Reports Full Year 2024 Financial Results and . . .
MORRISVILLE, N C , March 19, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today reported financial results for the full year ended December 31, 2024
- Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil . . .
YUTREPIA was designed using Liquidia’s PRINT ® technology, which enables the development of drug particles that are precise and uniform in size, shape and composition, and that are engineered for enhanced deposition in the lung following oral inhalation
|
|
|